Drugs
Researchers from Hong Kong have made a breakthrough in the treatment of non-small cell lung cancer (NSCLC), a type of cancer that accounts for approximately 85% of all lung cancer cases. According to a report published in Discovery Medicine, the Iressa Pan-Asia Study (IPASS) has shown that patients with a
Drugs
A candid discussion took place at the National Comprehensive Cancer Network's 15th Annual Conference on Clinical Practice Guidelines & Quality Cancer Care on March 11, 2010, between ABC News anchor and cancer survivor Sam Donaldson, a panel of experts, and patients and family members who have faced end
Drugs
Researchers have found that antiviral therapy significantly reduces the risk of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV)-related cirrhosis. This conclusion was drawn from a systematic review and meta-analysis of 20 studies, involving 4,700 patients, that compared untreated patients with those given interferon (IFN) alone
Drugs
Scientists have investigated the mechanism of 10-methoxy-9-nitrocamptothecin (MONCPT)-induced cell cycle arrest in A549 cells, finding that the p53 and p38 MAPK pathways are involved. This research has significant implications for anticancer therapy. By examining the effects of MONCPT on cell cycle distribution, protein expression, and RNA expression, researchers have
Drugs
Researchers from Vanderbilt University have made a groundbreaking discovery in the field of cancer treatment, detailing new data in mass spectrometry that can detect tumor dependence on the epidermal growth factor receptor (EGFR) pathway in cancer patients. The study, published in Cancer Epidemiology, Biomarkers & Prevention, analyzed serum proteomic profiles
Drugs
A new study provides insights into the management of hepatitis B virus (HBV) infection through liver transplantation, highlighting the need for a consensus standard regimen for treatment. The study, conducted by scientists in Hangzhou, People's Republic of China, reveals the limitations of current therapies and the potential benefits
Drugs
Researchers at St. Louis University, led by T. Kanda, have discovered that MBP-1 exhibits a significant antiproliferative effect on breast cancer cells. Their study, published in Cancer Research, found that administration of MBP-1 resulted in a substantial regression of primary and distant tumor growth in an immunocompetent mouse model. The
Drugs
Researchers at Tohoku University's Medical Department in Sendai, Japan have found that the Ndc80 complex, composed of CDCA1-KNTC2 and SPC24-SPC25 heterodimers, is significantly overexpressed in colorectal and gastric cancers. This overexpression is associated with poor prognosis in non-small cell lung cancers. The team used qRT-PCR to evaluate the
Communicable diseases
Millenia Hope Inc., a biotechnology corporation, has initiated a second trial for its malaria treatment, MMH Malarex, in the Republic of Central Africa (RCA). The trial, which will be conducted in three major cities, aims to study the effectiveness of MMH Malarex in children with noncomplicated malaria, who have no
Communicable diseases
Researchers at the University of Illinois at Urbana-Champaign have successfully synthesized QS-21A, a medicinally important molecule that enhances the body's immune response in vaccine therapies against aggressive diseases such as melanoma, breast cancer, small-cell lung cancer, prostate cancer, HIV-1, and malaria. This breakthrough could lead to more effective
Communicable diseases
Hepatitis C virus (HCV) infection has been linked to an increased risk of various types of cancer, including liver cancer and non-Hodgkin lymphoma. Research studies from Canada, Taiwan, and Japan have shed light on the molecular mechanisms underlying this association. The studies suggest that HCV infection can lead to the
Communicable diseases
Research conducted in the United States has found that a truncated form of the hepatitis C virus (HCV) core protein may play a role in the development of hepatocellular carcinomas (HCC). Studies have suggested that this truncated protein can enter hepatocyte nuclei, and mutations in the HCV core gene that
